Spinogenix

This study was designed to see if taking SPG302 daily for a long time is safe and helps slow Alzheimer's in people with mild-to-moderate symptoms. Only 12 people who had already been in an earlier SPG302 study were eligible. The trial was terminated early, so results are limited.

This study looked at the long-term safety of a daily oral drug called SPG302 in 16 people with ALS who had already taken part in an earlier study. The trial was stopped early, so results are limited. The main goal was to track side effects and changes in daily function.